急性缺血性卒中血管内再灌注后动脉内尿激酶治疗:POST-UK随机临床试验
POST-UK试验在中国35家医院纳入535例前循环大血管闭塞、血管内取栓后达到近完全至完全再灌注且未接受静脉溶栓的急性缺血性卒中患者,随机接受动脉内尿激酶10万IU或对照。90天无残疾生存率尿激酶组45.1% vs 对照组40.2%(调整RR 1.13,95%CI 0.94-1.36,P=0.19),死亡和症状性颅内出血无显著差异。
要点
- 取栓后近完全至完全再灌注患者加用动脉内尿激酶未显著提高90天无残疾生存率。
- 90天无残疾生存率尿激酶组45.1% vs 对照组40.2%,调整RR 1.13(95%CI 0.94-1.36,P=0.19)。
- 90天死亡率和48小时内症状性颅内出血两组无显著差异。
核心结论
- 对于大血管闭塞所致急性缺血性卒中患者,血管内取栓达到近完全至完全再灌注后辅助动脉内尿激酶未显著增加90天无残疾生存的可能性。
研究设计与样本
- 由研究者发起的随机、开放标签、盲法终点试验,在中国35家医院实施。
- 纳入535例前循环近端颅内大血管闭塞、最后已知良好时间24小时内、血管内取栓后达到近完全或完全再灌注且术前未接受静脉溶栓的患者。
- 招募时间为2022年11月15日至2024年3月29日,最终随访日期为2024年7月4日。
- 患者随机分配至动脉内尿激酶组(初始靶血管区域单次注射动脉内尿激酶10万IU;n=267)或对照组(未接受动脉内溶栓;n=267)。
主要发现
- 90天无残疾生存(改良Rankin量表评分0或1)率尿激酶组为45.1%(120/266),对照组为40.2%(107/266),调整风险比1.13(95%CI 0.94-1.36;P=0.19)。
- 90天死亡率尿激酶组18.4% vs 对照组17.3%,调整风险比1.06(95%CI 0.71-1.59;P=0.77)。
- 48小时内症状性颅内出血发生率尿激酶组4.1% vs 对照组4.1%,调整风险比1.05(95%CI 0.45-2.44;P=0.91)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Persisting or new thrombi in the distal arteries and the microcirculation have been reported to limit the benefits of successful endovascular thrombectomy for patients with acute ischemic stroke. It remains uncertain whether intra-arterial thrombolysis by urokinase following near-complete to complete reperfusion by thrombectomy improves outcomes among patients with ischemic stroke due to large vessel occlusion. OBJECTIVE: To assess the efficacy and adverse events of intra-arterial urokinase after near-complete to complete reperfusion by thrombectomy for acute ischemic stroke due to large vessel occlusion. DESIGN, SETTING, AND PARTICIPANTS: This investigator-initiated, randomized, open-label, blinded-end point trial was implemented at 35 hospitals in China, enrolling 535 patients with proximal intracranial large vessel occlusion presenting within 24 hours of time last known well, who achieved near-complete or complete reperfusion by endovascular thrombectomy and did not receive intravenous thrombolysis prior to the procedure. Recruitment took place between November 15, 2022, and March 29, 2024, with final follow-up on July 4, 2024. INTERVENTIONS: Eligible patients were randomly assigned to the intra-arterial urokinase group (a single dose of intra-arterial 100 000 IU urokinase injected in the initial target territory; n = 267) or control group (without intra-arterial thrombolysis; n = 267). MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was the percentage of patients achieving survival without disability (modified Rankin Scale score of 0 or 1) at 90 days. The primary safety outcomes were mortality at 90 days and incidence of symptomatic intracranial hemorrhage within 48 hours. RESULTS: A total of 535 patients were enrolled (median age, 69 years; 223 [41.8%] female) and 532 (99.6%) completed the trial. The percentage of patients with survival without disability at 90 days was 45.1% (120/266) in the intra-arterial urokinase group and 40.2% (107/266) in the control group (adjusted risk ratio, 1.13 [95% CI, 0.94-1.36]; P = .19). Mortality at 90 days (18.4% vs 17.3%, respectively; adjusted hazard ratio, 1.06 [95% CI, 0.71-1.59]; P = .77) and incidence of symptomatic intracranial hemorrhage (4.1% vs 4.1%, respectively; adjusted risk ratio, 1.05 [95% CI, 0.45-2.44]; P = .91) were not significantly different between groups. CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke due to large vessel occlusion, adjunct intra-arterial urokinase after near-complete to complete reperfusion by endovascular thrombectomy did not significantly increase the likelihood of survival without disability at 90 days. TRIAL REGISTRATION: ChiCTR.org.cn Identifier: ChiCTR2200065617.
引用
- Liu C, Guo C, Li F, et al. Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke: The POST-UK Randomized Clinical Trial. JAMA. 2025. PMID: 39804674. doi:10.1001/jama.2024.23480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。